- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Indonesia grants emergency use nod to Walvax Biotechnology mRNA COVID vaccine AWcorna
Jakarta: Indonesia said it has granted emergency use approval to an mRNA COVID-19 vaccine developed by a Chinese company, becoming the first country, ahead of even China, to do so.
Indonesia's food and drugs agency (BPOM) greenlighted the use of Walvax Biotechnology's mRNA vaccine, which has been in development for more than two years and targets the original strain of the coronavirus.
The approval comes as somewhat of a surprise as Walvax, which has been conducting large late-stage trials of the vaccine in several countries including Indonesia, Mexico and China, has yet to publish efficacy readings that would show how well it can reduce the risk of COVID cases and deaths.
Penny Lukito, head of the agency, told reporters the vaccine, now known as AWcorna, was 83.58% effective against wild-type coronavirus strains considered common and normal, though she added that its efficacy drops to 71.17% for the highly contagious Omicron variant.
She did not provide details of the data and did not respond to Reuters queries seeking further comment.
Walvax declined to comment. Share reaction for the Chinese company was muted, with the stock rising just 0.5%.
Indonesia has previously granted emergency use approvals to other Chinese COVID shots before detailed efficacy data became available, though that was earlier on in the pandemic when Western-made products were in short supply.
China has several mRNA candidates in development but the Walvax vaccine is the only candidate in large late-stage clinical trials.
It was not immediately clear how widely the newly approved shot will be used in Indonesia, where more than 63% of its population is fully vaccinated. Health experts around the world also recommend using so-called bivalent COVID vaccines, which target both the original strain and the Omicron variant.
Indonesia also uses mRNA COVID vaccines made by Pfizer -BioNTech and Moderna, but the AWcorna shot has a longer shelf life, remaining stable at 2-8 degrees Celsius for at least six months, according to its researchers.
That could make the vaccine ideal for Indonesia, an archipelago of thousands of islands, and other countries which have poor logistics in remote areas.
BPOM said the vaccine's less stringent storage requirements suited Indonesia, a tropical country, and it could be used as both a primary and a booster shot for adults.
The vaccine will be locally produced by an Indonesian firm, Etana Biotechnologies.
Dicky Budiman, an Indonesian epidemiologist at Australia's Griffith University, said producing AWcorna at home via technology transfer would help the country develop sufficient expertise as it seeks to prepare for new variants and possible shortages of vaccines.
"It's important and strategic," he said.
Walvax co-developed the vaccine with Suzhou Abogen Biosciences and a Chinese military-backed institution.
Walvax and Suzhou Abogen are also separately working on their own mRNA candidates that target coronavirus variants.
For its part, China has not approved any Western-made COVID shots and its approved vaccine portfolio does not yet include vaccines that specifically target the Omicron variant.
Read also: AstraZeneca, Merck get Chinese nod for Lynparza to treat ovarian cancer
COVID 19coronaviruscoronavirus vaccineWalvax BiotechnologyAWcornaSuzhou Abogen BiosciencesEtana Biotechnologies
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Next Story